Drug Monograph
Fluconazole (Diflucan)
fluconazole
Pharmacokinetic Profile
Half-Life
~30 h (range 20–50 h)
Metabolism
Minimal (~11% as metabolites)
Protein Binding
11–12%
Bioavailability
>90% (oral)
Volume of Distribution
~0.7 L/kg (total body water)
Clinical Information
Drug Class
Triazole Antifungal
Available Doses
50, 100, 150, 200 mg tabs; 10 & 40 mg/mL susp; 2 mg/mL IV
Route
Oral, IV
Renal Adjustment
Yes — reduce dose if CrCl <50 mL/min
Hepatic Adjustment
Use with caution; monitor LFTs
Pregnancy
Avoid (former Cat. D) — teratogenic at high doses
Lactation
Compatible — excreted in breast milk at concentrations similar to plasma; doses below neonatal therapeutic range
Schedule / Legal Status
Prescription only (non-scheduled)
Generic Available
Yes
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Vaginal candidiasis | Adults | Monotherapy | FDA Approved |
| Oropharyngeal candidiasis | Adults and pediatrics (≥6 months) | Monotherapy | FDA Approved |
| Esophageal candidiasis | Adults and pediatrics | Monotherapy | FDA Approved |
| Systemic Candida infections (candidemia, disseminated candidiasis, pneumonia) | Adults and pediatrics | Monotherapy or step-down | FDA Approved |
| Candida urinary tract infections & peritonitis | Adults | Monotherapy | FDA Approved |
| Cryptococcal meningitis | Adults and pediatrics | Consolidation / maintenance | FDA Approved |
| Prophylaxis of candidiasis in BMT recipients | Adults receiving cytotoxic chemo or radiation | Prophylaxis | FDA Approved |
Fluconazole is a cornerstone antifungal agent widely used across mucosal and systemic Candida infections, as well as cryptococcal disease. Its near-complete oral bioavailability and excellent CNS penetration make it particularly valuable for step-down therapy after intravenous induction and for long-term suppressive treatment in immunocompromised patients. Clinicians should note that fluconazole has limited or no activity against Candida krusei (intrinsic resistance) and variable activity against Candida glabrata, for which susceptibility testing is recommended.
Off-Label Uses
Blastomycosis — mild-to-moderate, non-CNS disease as step-down after itraconazole or amphotericin B. Evidence quality: Moderate
Coccidioidomycosis — non-meningeal disease or long-term suppression of coccidioidal meningitis. Evidence quality: Moderate
Histoplasmosis — alternative agent for mild disease when itraconazole is not tolerated. Evidence quality: Low
Tinea versicolor / dermatophytosis — systemic treatment when topical agents fail. Evidence quality: Moderate
Breast candidiasis in nursing mothers — loading dose of 400 mg then 200 mg daily for at least 2 weeks. Evidence quality: Moderate
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Uncomplicated vulvovaginal candidiasis | 150 mg single dose | N/A | 150 mg | One-time oral dose; no loading required |
| Recurrent vulvovaginal candidiasis (suppressive) | 150 mg q72h × 3 doses | 150 mg once weekly | 150 mg/week | Induction for 3 doses then weekly maintenance for 6 months (IDSA guideline) |
| Oropharyngeal candidiasis | 200 mg on Day 1 | 100 mg daily | 200 mg/day | Treat for minimum 2 weeks to reduce relapse risk Loading dose = twice daily dose on Day 1 |
| Esophageal candidiasis | 200 mg on Day 1 | 100–200 mg daily | 400 mg/day | Minimum 3 weeks and at least 2 weeks after symptom resolution |
| Candidemia / disseminated candidiasis — step-down | 800 mg on Day 1 | 400 mg daily | 800 mg/day | Step-down after clinical improvement on echinocandin; total duration ≥2 weeks after first negative blood culture (IDSA 2016) |
| Candida urinary tract infection | 200 mg on Day 1 | 100–200 mg daily | 200 mg/day | Duration typically 2 weeks for symptomatic cystitis |
| Cryptococcal meningitis — consolidation | 400 mg on Day 1 | 400 mg daily | 800 mg/day | Following ≥2 weeks of amphotericin B + flucytosine induction; consolidation for 8 weeks, then maintenance 200 mg/day for ≥1 year (WHO/IDSA) |
| Cryptococcal meningitis — long-term suppression | 200 mg daily | 200 mg daily | 200 mg/day | Minimum 1 year; consider discontinuation with immune reconstitution (CD4 >100 for ≥3 months on ART) |
| BMT candidiasis prophylaxis | 400 mg daily | 400 mg daily | 400 mg/day | Begin several days before anticipated neutropenia; continue 7 days after ANC >1000/mm³ |
Pediatric Dosing (≥6 months unless specified)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Oropharyngeal candidiasis | 6 mg/kg on Day 1 | 3 mg/kg daily | 12 mg/kg/day | Minimum 2 weeks treatment duration |
| Esophageal candidiasis | 6 mg/kg on Day 1 | 3–12 mg/kg daily | 12 mg/kg/day | At least 3 weeks and 2 weeks after symptom clearance |
| Systemic candidiasis | 12 mg/kg on Day 1 | 6–12 mg/kg daily | 12 mg/kg/day | Minimum 3 weeks and 2 weeks after resolution; doses >600 mg/day not recommended |
| Cryptococcal meningitis | 12 mg/kg on Day 1 | 6–12 mg/kg daily | 12 mg/kg/day | Duration 10–12 weeks after CSF culture negative |
Renal Dose Adjustment (Multi-Dose Regimens Only)
| Creatinine Clearance | Dose Adjustment | Notes |
|---|---|---|
| >50 mL/min | 100% of recommended dose | No adjustment required |
| ≤50 mL/min (no dialysis) | 50% of recommended dose | Still give full loading dose on Day 1 |
| Hemodialysis | 100% of recommended dose after each session | 3-hour HD removes ~50% of plasma levels; administer post-dialysis |
Clinical Pearl — Loading Dose Strategy
Because of the long half-life (~30 hours) and time to steady state (5–10 days), the FDA PI recommends a loading dose of twice the maintenance dose on Day 1 for all multi-dose regimens. This brings plasma concentrations close to steady-state by Day 2. The oral and IV doses are identical due to near-complete oral bioavailability (>90%), making oral-to-IV conversion straightforward at a 1:1 ratio.
Pharmacology
Mechanism of Action
Fluconazole is a synthetic bis-triazole antifungal that selectively inhibits the fungal cytochrome P450 enzyme lanosterol 14α-demethylase (CYP51). This enzyme catalyzes a critical step in the biosynthesis of ergosterol, the principal sterol component of fungal cell membranes. By blocking 14α-demethylation of lanosterol, fluconazole causes accumulation of methylated sterol intermediates and depletion of ergosterol, leading to increased membrane permeability, disruption of membrane-bound enzyme systems, and ultimately growth arrest of susceptible fungi. The selectivity for fungal over mammalian CYP51 accounts for its favorable therapeutic index. The drug demonstrates concentration-independent (time-dependent) activity, with clinical efficacy correlating with the ratio of AUC to the minimum inhibitory concentration (AUC/MIC).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | >90% oral bioavailability; Tmax 1–2 h; dose-proportional AUC across 50–400 mg range | Food and gastric pH do not affect absorption; oral and IV doses are interchangeable at 1:1 ratio |
| Distribution | Vd ~0.7 L/kg (approximates total body water); protein binding 11–12%; CSF:plasma ratio ~80% | Excellent penetration into CSF, saliva, sputum, vaginal tissue, urine, and skin — suitable for meningitis and deep-seated infections |
| Metabolism | Metabolically stable; only ~11% excreted as metabolites; inhibits CYP2C19 (strong), CYP2C9 and CYP3A4 (moderate) | Minimal hepatic metabolism means drug-drug interactions arise primarily from fluconazole inhibiting other drugs’ metabolism, not from altered fluconazole levels |
| Elimination | t½ ~30 h (range 20–50 h); ~80% renally excreted as unchanged drug; clearance 0.23 mL/min/kg | Dose reduction required if CrCl ≤50 mL/min; dialyzable (~50% removal in 3-hour HD session); steady state by Day 5–10 with daily dosing |
Side Effects
≥10%
Very Common (Single-Dose 150 mg for Vaginal Candidiasis)
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 13% | Self-limiting; typically resolves within 24 hours; managed with simple analgesics |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 3.7% (multi-dose); 7% (single-dose) | Most frequent GI complaint; taking with food may reduce discomfort despite no effect on absorption |
| Abdominal pain | 1.7% (multi-dose); 6% (single-dose) | Usually mild and transient; reassess if persistent beyond treatment course |
| Skin rash | 1.8% | Monitor closely in immunocompromised patients — may herald more serious dermatologic reactions |
| Headache | 1.9% (multi-dose) | Incidence in multi-dose regimens lower than single-dose vaginal candidiasis trials |
| Vomiting | 1.7% | Consider IV route if oral administration is not tolerated |
| Diarrhea | 1.5% (multi-dose); 3% (single-dose) | Self-limiting in most cases |
| Dyspepsia | 1% | Does not typically require discontinuation |
| Dizziness | 1% | Caution with driving until effect is known |
| Taste perversion | 1% | Metallic taste; reversible upon completion of therapy |
| Transaminase elevations (asymptomatic) | 1–13% | Higher incidence with concomitant hepatotoxic drugs or severe underlying disease; typically reversible on discontinuation |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hepatotoxicity (clinical hepatitis, cholestasis, fulminant hepatic failure) | Rare (~1% for transaminase >8× ULN) | Days to weeks | Discontinue immediately if clinical signs of liver disease develop; fatal cases reported, mostly in patients with serious underlying conditions |
| QT prolongation / Torsades de pointes | Rare | Any time during therapy | Obtain baseline ECG in high-risk patients; avoid concomitant QT-prolonging drugs; discontinue and obtain cardiology consultation if symptomatic arrhythmia occurs |
| Stevens-Johnson syndrome / Toxic epidermal necrolysis | Very rare | 1–4 weeks | Immediately discontinue fluconazole; dermatology and ICU referral; permanent discontinuation required |
| Anaphylaxis / angioedema | Very rare | Minutes to hours after dose | Emergency management with epinephrine; permanent discontinuation; document allergy to azoles |
| Seizures | Rare | Variable | Assess for contributing factors (electrolytes, CNS disease); consider dose reduction or discontinuation |
| Agranulocytosis / leukopenia / thrombocytopenia | Rare | Variable; often in prolonged courses | Check CBC; discontinue if significant cytopenias develop; usually reversible |
| Adrenal insufficiency (reversible) | Very rare | Weeks to months with prolonged therapy | Consider cortisol testing if fatigue, weight loss, or hypotension develop on chronic therapy |
| Alopecia | Rare | Weeks to months | Generally reversible after discontinuation; mostly reported at doses ≥400 mg/day for prolonged periods |
Discontinuation
Discontinuation Rates
Adults (Multi-Dose, ≥7 Days)
1.5% clinical adverse events
Additional 1.3% discontinued for laboratory abnormalities. Overall, 16% experienced any adverse event in trials of ≥7 days.
Pediatrics (1 day–17 years)
2.3% clinical adverse events
Additional 1.4% discontinued for laboratory abnormalities. 13% experienced treatment-related adverse events overall.
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Elevated transaminases / alkaline phosphatase | 1.3–1.4% | Most common laboratory reason; higher incidence with concomitant hepatotoxic agents |
| Skin rash | <1% | Discontinue if rash progresses, especially in immunocompromised patients |
| GI intolerance (nausea, vomiting, diarrhea) | <1% | Rarely severe enough to warrant stopping treatment |
Managing Hepatotoxicity Risk
Hepatic injury is the most clinically significant adverse effect of fluconazole. Serious hepatic reactions, including fatalities, have been reported predominantly in patients with severe underlying diseases (AIDS, malignancies) who were also taking multiple hepatotoxic medications. Baseline LFTs should be obtained before initiating courses longer than 14 days. Treatment should be discontinued if transaminases rise above 3 times the upper limit of normal with symptoms, or above 5 times ULN regardless of symptoms. Inform patients to report right upper quadrant pain, dark urine, jaundice, or unexplained fatigue promptly.
Drug Interactions
Fluconazole is a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4. Its long half-life means that enzyme inhibition persists for 4–5 days after the last dose. Fluconazole is metabolically stable itself, so clinically significant interactions arise almost exclusively from fluconazole raising levels of co-administered drugs. Additionally, fluconazole carries a risk of QT prolongation, which is additive with other QTc-prolonging agents.
Major
Warfarin
MechanismCYP2C9 inhibition raises S-warfarin levels
EffectIncreased INR and risk of bleeding (bruising, GI bleeding, hematuria)
ManagementMonitor INR closely upon initiation and discontinuation of fluconazole; empirically reduce warfarin dose by 25–50%
FDA PI
Major
Cisapride / Pimozide / Erythromycin
MechanismCYP3A4 inhibition + additive QTc prolongation
EffectRisk of Torsades de pointes and sudden cardiac death
ManagementConcomitant use is contraindicated (FDA PI)
FDA PI
Major
Cyclosporine
MechanismCYP3A4 inhibition increases cyclosporine AUC by ~92%
EffectNephrotoxicity, neurotoxicity from supratherapeutic cyclosporine levels
ManagementMonitor cyclosporine trough levels closely; anticipate 30–50% dose reduction of cyclosporine
FDA PI
Major
Tacrolimus
MechanismCYP3A4 inhibition raises tacrolimus concentrations
EffectNephrotoxicity; risk of supratherapeutic tacrolimus levels
ManagementReduce oral tacrolimus dose based on trough monitoring; check levels within 3 days of starting fluconazole
FDA PI
Moderate
Phenytoin
MechanismCYP2C9 inhibition increases phenytoin AUC
EffectPhenytoin toxicity (nystagmus, ataxia, sedation)
ManagementMonitor phenytoin levels and adjust dose accordingly
FDA PI
Moderate
Oral Sulfonylureas (e.g., Glyburide)
MechanismCYP2C9 inhibition raises sulfonylurea levels (glyburide AUC increased ~44%)
EffectClinically significant hypoglycemia; one fatality reported
ManagementIntensify blood glucose monitoring; consider reducing sulfonylurea dose during fluconazole therapy
FDA PI
Moderate
Midazolam / Triazolam
MechanismCYP3A4 inhibition (oral fluconazole increased midazolam AUC by 272%)
EffectProfound and prolonged sedation
ManagementReduce benzodiazepine dose substantially; consider alternative non-CYP3A4 sedative (e.g., lorazepam)
FDA PI
Moderate
Rifampin
MechanismRifampin induces fluconazole metabolism, reducing fluconazole AUC by ~23% and shortening half-life
EffectPotential sub-therapeutic fluconazole concentrations
ManagementConsider increasing fluconazole dose; monitor for treatment failure
FDA PI
Moderate
Statins (Simvastatin, Atorvastatin)
MechanismCYP3A4 inhibition increases statin plasma levels
EffectIncreased risk of myopathy and rhabdomyolysis
ManagementTemporarily withhold statin during short fluconazole courses; if concurrent use is necessary, use lowest statin dose and monitor for muscle symptoms
Lexicomp
Minor
Theophylline
MechanismDecreased theophylline clearance (~16%); AUC increased ~21%
EffectPossible theophylline toxicity at higher doses
ManagementMonitor theophylline levels if doses are in the upper range
FDA PIMonitoring
-
Hepatic Function (AST, ALT, ALP, bilirubin)
Baseline; then periodically during prolonged therapy
Routine Obtain baseline LFTs before courses exceeding 14 days. Repeat at 2 weeks, then monthly for prolonged courses. Discontinue if transaminases rise >3× ULN with symptoms or >5× ULN without symptoms. Higher vigilance needed when co-prescribing hepatotoxic medications (rifampin, isoniazid, valproic acid). -
Renal Function (Cr, CrCl)
Baseline; periodically in at-risk patients
Routine Essential for dose adjustment since ~80% of drug is renally excreted unchanged. Reassess CrCl if renal function changes during treatment. Critical in elderly patients and those receiving nephrotoxic co-medications (cyclosporine, tacrolimus, amphotericin B). -
ECG / QTc Interval
Baseline in high-risk patients
Trigger-based Obtain baseline ECG in patients with pre-existing cardiac disease, electrolyte abnormalities (hypokalemia, hypomagnesemia), or concurrent QTc-prolonging medications. Repeat if arrhythmia symptoms develop. -
Electrolytes (K+, Mg2+)
Baseline and as needed
Trigger-based Hypokalemia reported; correct electrolyte abnormalities before initiating fluconazole to reduce arrhythmia risk. -
INR / PT
Within 3–5 days of starting fluconazole and at discontinuation
Trigger-based Required for all patients on warfarin or other coumarins. Fluconazole inhibits CYP2C9, significantly raising warfarin levels. INR may remain elevated for 4–5 days after stopping fluconazole due to long half-life. -
Blood Glucose
Closely during concurrent sulfonylurea use
Trigger-based CYP2C9 inhibition can cause clinically significant hypoglycemia with sulfonylureas. Consider reducing sulfonylurea dose proactively. -
Skin Assessment
Each visit during therapy
Routine Monitor for rash development, particularly in immunocompromised patients. Discontinue if rash progresses or blistering/mucosal involvement occurs (possible SJS/TEN).
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to fluconazole or any other azole antifungal agent
- Coadministration with cisapride, pimozide, or erythromycin at fluconazole doses ≥400 mg/day — risk of fatal cardiac arrhythmias (QT prolongation, Torsades de pointes)
- Coadministration with drugs known to prolong QT interval and metabolized via CYP3A4 — including astemizole and quinidine
Relative Contraindications (Specialist Input Recommended)
- Pregnancy — chronic high-dose fluconazole (400–800 mg/day) in the first trimester is associated with a distinct pattern of congenital anomalies. Use during pregnancy only when the anticipated benefit outweighs the risk to the fetus and only for life-threatening fungal infections. Single low-dose (150 mg) for vaginal candidiasis remains controversial but current FDA guidance advises caution. Requires documented risk-benefit discussion.
- Pre-existing hepatic disease — use only if benefit clearly outweighs risk, with close LFT monitoring. Consult hepatology for patients with Child-Pugh B/C cirrhosis.
- Congenital or acquired long QT syndrome — fluconazole carries QT-prolongation risk; cardiology input recommended before prescribing.
Use with Caution
- Renal impairment (CrCl ≤50 mL/min) — dose reduction required for multi-dose regimens
- Concurrent use of multiple hepatotoxic agents (rifampin, isoniazid, valproic acid, phenytoin) — increased risk of liver injury
- Proarrhythmic conditions — electrolyte imbalances (hypokalemia, hypomagnesemia), heart failure, bradycardia, concurrent QTc-prolonging medications
- Elderly patients — more likely to have decreased renal function; adjust dose based on CrCl
- Patients on narrow therapeutic index drugs metabolized by CYP2C9, CYP2C19, or CYP3A4 — monitor closely for toxicity of co-administered drugs
FDA Safety Communication
Fetal Risk with Chronic High-Dose Use in Pregnancy
The FDA has issued a safety communication regarding the association between chronic high-dose fluconazole (400–800 mg/day) during the first trimester and a rare pattern of birth defects including craniosynostosis, brachycephaly, abnormal facies, cleft palate, bowed long bones, and congenital heart defects. This risk has not been established with single low-dose use (150 mg). Fluconazole should be avoided during pregnancy except for life-threatening fungal infections where the potential benefit outweighs the risk. Women of reproductive potential should use effective contraception during treatment and for at least one week after the final dose.
Patient Counselling
Purpose of Therapy
Fluconazole is an antifungal medication that works by disrupting the cell membranes of fungi, preventing them from growing and spreading. Depending on the type of infection, treatment may require just a single dose (for vaginal yeast infections) or a longer course lasting several weeks to months (for more serious fungal infections). It is important to complete the full course of treatment even if symptoms improve early, because stopping too soon may allow the infection to return or become resistant to future treatment.
How to Take
Fluconazole tablets can be taken with or without food, as food does not affect absorption. For liquid suspensions, shake the bottle well before each dose and measure using the provided oral syringe or measuring cup — not a household teaspoon. The oral and intravenous forms deliver equivalent drug exposure, so patients transitioned from IV to oral at discharge can be reassured that efficacy is maintained. Store tablets and suspension at room temperature; discard unused liquid suspension after 14 days.
Nausea & Stomach Discomfort
Tell patient
GI symptoms such as nausea, abdominal pain, and diarrhea are the most common side effects and are usually mild. Taking the medication with a light meal may reduce nausea. These effects are generally short-lived and improve as the body adjusts.
Call prescriber
If vomiting is severe enough that doses cannot be kept down, or if diarrhea is persistent, bloody, or accompanied by fever.
Liver Health
Tell patient
Rarely, fluconazole can affect the liver. This risk is higher in patients taking other medications that stress the liver. Blood tests to check liver function may be needed during treatment.
Call prescriber
Immediately if experiencing yellowing of the skin or eyes (jaundice), dark-colored urine, unusually pale stools, right-sided abdominal pain, or persistent unexplained fatigue and loss of appetite.
Skin Rash
Tell patient
Mild skin rash occurs in about 2% of patients. Most rashes are minor and self-limiting. However, in very rare cases, a serious skin reaction can develop.
Call prescriber
Urgently if a rash is spreading rapidly, blistering, peeling, or accompanied by mouth sores, fever, or sore eyes — these could be signs of a serious reaction requiring immediate medical attention.
Heart Rhythm
Tell patient
Fluconazole can occasionally affect the heart’s electrical rhythm, particularly in patients who take other medications that do the same or who have underlying heart conditions. This risk is generally very low with standard doses.
Call prescriber
If experiencing rapid or irregular heartbeat, palpitations, fainting, or unexplained dizziness.
Pregnancy & Contraception
Tell patient
High-dose, prolonged fluconazole use during the first trimester of pregnancy has been linked to birth defects. Women who could become pregnant should use reliable contraception during treatment and for at least one week after the last dose.
Call prescriber
Immediately if pregnancy is confirmed or suspected during treatment.
Drug Interactions
Tell patient
Fluconazole interacts with many common medications, including blood thinners (warfarin), certain diabetes pills, cholesterol-lowering drugs, and some sedatives. Always inform all healthcare providers (including dentists) about fluconazole use. The effects on other medications can persist for several days after stopping fluconazole.
Call prescriber
Before starting any new prescription or over-the-counter medication while on fluconazole.
Sources
Regulatory (PI / SmPC)
- Pfizer Inc. DIFLUCAN (fluconazole) Prescribing Information. U.S. Food and Drug Administration. https://labeling.pfizer.com/showlabeling.aspx?id=575 Primary source for all FDA-approved indications, dosing, pharmacokinetics, adverse reactions, drug interactions, and contraindications.
- U.S. Food and Drug Administration. DIFLUCAN (fluconazole) Label (2021 revision). accessdata.fda.gov Most recent FDA label revision with updated safety information including QT prolongation risk and pregnancy warnings.
- DailyMed — National Library of Medicine. Fluconazole Tablet Label. dailymed.nlm.nih.gov NIH-hosted prescribing information used to cross-reference adverse event incidence rates and pediatric safety data.
Key Clinical Trials & Guidelines
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ933 IDSA guideline providing treatment algorithms for candidemia step-down therapy and duration of treatment recommendations.
- Perfect JR, Dismukes WE, Dromer F, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322. doi:10.1086/649858 IDSA guideline for cryptococcal meningitis management including induction, consolidation, and maintenance fluconazole dosing in HIV-positive patients.
- World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. 2022. who.int WHO guideline supporting fluconazole as a key agent in cryptococcal meningitis consolidation and maintenance worldwide.
- Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876-883. doi:10.1056/NEJMoa033114 Landmark RCT establishing the weekly 150 mg fluconazole suppressive regimen for recurrent vulvovaginal candidiasis over 6 months.
Mechanistic / Basic Science
- Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24-34. doi:10.1128/AAC.00705-08 Discusses the pharmacodynamic target of AUC/MIC ratio for fluconazole and its correlation with clinical efficacy.
- Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73-85. doi:10.1016/S1473-3099(02)00181-0 Review of azole resistance mechanisms including ERG11 mutations and efflux pump upregulation relevant to fluconazole resistance in C. glabrata and C. krusei.
Pharmacokinetics / Special Populations
- Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Suppl 3):S318-S326. doi:10.1093/clinids/12.supplement_3.s318 Foundational PK study establishing key parameters: Vd 0.7 L/kg, protein binding 12%, t½ ~30 hours, and renal excretion ~80%.
- Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet. 1997;33(1):52-77. doi:10.2165/00003088-199733010-00005 Comprehensive PK review covering bioavailability, distribution into body fluids, dosing in renal impairment, and hemodialysis guidance.
- Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52(11):4043-4049. doi:10.1128/AAC.00569-08 Pediatric PK study characterizing the longer half-life in neonates (40–60 hours) and basis for weight-based dosing in young infants.
- Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28(9):1805-1808. doi:10.1248/bpb.28.1805 In vitro study quantifying fluconazole’s inhibitory potency against CYP isoforms, supporting its classification as a strong CYP2C19 and moderate CYP2C9/3A4 inhibitor.